Dublin, Aug. 15, 2016 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Global Biosimilars Market 2016-2020" report to their offering. Biosimilars are defined as the follow-on versions of original biological medicines. These are separately developed after the patent protecting the original product has expired. Biosimilars are intended to have the same MOA as original biological drugs and are designed to treat the same diseases as the innovator's product. They have many similarities, but are not identical to, the reference biopharmaceutical product. This comprehensive report forecasts the global biosimilars market to grow at a CAGR of 55.52% during the period 2016-2020. The report states that the reluctant nature of physicians to prescribe biosimilars will be a challenge for the market. Physicians are reluctant to prescribe biosimilars to patients, as biologics cannot be substituted with these drugs. Biologics are developed using a living system or a genetically modified organism.
A slight variation in the manufacturing process, in terms of conditions and the formulation of biosimilar products can affect the safety and efficacy of the final product. Biosimilars can also not be used during post-marketing surveillance as the substitution of drugs is prohibited in a country during this period. Also, similar to generic drugs, physicians do not receive financial incentives for prescribing biosimilars. Questions Answered:
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?
Companies Mentioned Include:
- Sandoz
- Hospira
- Teva Pharmaceuticals
- STADA
- Biocon
- Celltrion
- Dr Reddy's
- 3SBio
- Amgen
- Apotex
- Aspen
- Coherus Biosciences
- Daiichi Sankyo
- Emcure Pharmaceuticals
- Gedeon Richter
- GeneScience Pharmaceuticals
- GSK
- Hetero Drugs
- iBio
- Samsung Biologics
- Sanofi
- Synthon
- Wockhardt
Report Structure:
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Market research methodology PART 04: Introduction PART 05: Pipeline portfolio
PART 06: Market landscape PART 07: Market segmentation by application PART 08: Market segmentation by end-user PART 09: Geographical segmentation PART 10: Market drivers PART 11: Impact of drivers
PART 12: Market challenges PART 13: Impact of drivers and challenges
PART 14: Market trends PART 15: Vendor landscape PART 16: Appendix PART 17: About the Author
For more information about this report visit http://www.researchandmarkets.com/research/xvszv2/global
CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716
